Phase II Trial of Weekly Gemcitabine and Herceptin in the Treatment of Patients With HER-2 Overexpressing Metastatic Breast Cancer
Upon determination of eligibility, all patients will be receive:
Gemcitabine + Trastuzumab
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
assess the feasibility and toxicity of the combination of weekly gemcitabine and trastuzumab in the treatment of metastatic breast cancer overexpressing Her-2.
18 Months
No
Denise A. Yardley, MD
Principal Investigator
Sarah Cannon Research Institute
United States: Food and Drug Administration
SCRI BRE 44
NCT00193063
July 2001
August 2009
Name | Location |
---|